Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation

BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns of dabigatran use among patients enrolled in the Outcomes Registry for Better I...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinberg, Benjamin A., Holmes, DaJuanicia N., Piccini, Jonathan P., Ansell, Jack, Chang, Paul, Fonarow, Gregg C., Gersh, Bernard, Mahaffey, Kenneth W., Kowey, Peter R., Ezekowitz, Michael D., Singer, Daniel E., Thomas, Laine, Peterson, Eric D., Hylek, Elaine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886732/
https://www.ncbi.nlm.nih.gov/pubmed/24275632
http://dx.doi.org/10.1161/JAHA.113.000535

Ejemplares similares

Ejemplares similares